Real-world (rw) treatment patterns, sequencing, and outcomes in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) receiving avelumab first-line maintenance (1LM) in the US.

Authors

Helen H. Moon

Kaiser Permanente, Riverside, CA

Helen H. Moon , Mairead Kearney , Seyed Hamidreza Mahmoudpour , Chiemeka Ike , Valerie A. Morris , Andrew Rava , Sonia Kim , Haiyan Sun , Marley Boyd , Gabriel Gomez Rey

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Genitourinary Cancers Symposium

bookmark_border

READY: Real-world data from an Italian compassionate use program of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la/mUC).

First Author: Lorenzo Antonuzzo

insert_chart_outlined

Poster

2024 ASCO Genitourinary Cancers Symposium

bookmark_border

Subgroup analyses from READY: Real-world data from an Italian compassionate use program (CUP) of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la/mUC).

First Author: Sergio Bracarda

insert_chart_outlined

Poster

2023 ASCO Genitourinary Cancers Symposium

bookmark_border

Assessment of treatment patterns and real-world outcomes following changes in the treatment paradigm for locally advanced/metastatic urothelial carcinoma (la/mUC) in the US.

First Author: Melissa Kirker

insert_chart_outlined

Poster

2018 Genitourinary Cancers Symposium

bookmark_border

Overall survival and treatment patterns among real-world patients with locally advanced or metastatic urothelial carcinoma treated with first-line therapy.

First Author: Jason C Simeone